Biomarkers for Alzheimer’s Disease Drug Development

Description

This volume aims to build a new generation of experts with a broader understanding of key topics in the Alzheimer’s disease field. Chapters guide readers through innovative approaches to the discovery of novel biomarkers in cerebrospinal fluid, innovation in blood-based biomarkers, a comprehensive overview of magnetic resonance imaging and molecular imaging approaches and their value for developing drugs for Alzheimer’s disease, cutting-edge developments in neuropathology and their relevance for Alzheimer’s disease trials, novel genomic strategies for biomarker development, and related topics including neuropsychological testing and advanced analytical methods.Written in the highly successful Methods in Molecular Biology series format, chapters include introductions to their respective topics, lists of the necessary materials and reagents, step-by-step, readily reproducible laboratory protocols, and tips on troubleshooting and avoiding known pitfalls. Authoritative and cutting-edge, Biomarkers for Alzheimer's Disease Drug Development aims to ensure successful results in the further study of this vital field. Front Matter ....Pages i-xv Front Matter ....Pages 1-1 Epidemiology of Dementia: The Burden on Society, the Challenges for Research (Frank J. Wolters, M. Arfan Ikram)....Pages 3-14 Population-Based Approaches to Alzheimer’s Disease Prevention (Robert Perneczky)....Pages 15-29 Systems Biology Methods for Alzheimer’s Disease Research Toward Molecular Signatures, Subtypes, and Stages and Precision Medicine: Application in Cohort Studies and Trials (Juan I. Castrillo, Simone Lista, Harald Hampel, Craig W. Ritchie)....Pages 31-66 Front Matter ....Pages 67-67 CSF Lipidomics Analysis: High-Resolution Mass Spectrometry Analytical Platform (Paul L. Wood, Randall L. Woltjer)....Pages 69-74 CSF N-Glycomics Using MALDI MS Techniques in Alzheimer’s Disease (Angelo Palmigiano, Angela Messina, Rosaria Ornella Bua, Rita Barone, Luisa Sturiale, Mario Zappia et al.)....Pages 75-91 MicroRNA Profiling of Alzheimer’s Disease Cerebrospinal Fluid (Johannes Denk, Holger Jahn)....Pages 93-107 Front Matter ....Pages 109-109 Validation of a Chemiluminescence Immunoassay for Measuring Amyloid-β in Human Blood Plasma (Jonathan Vogelgsang, Jens Wiltfang, Hans W. Klafki)....Pages 111-124 Mass Spectrometry-Based Metabolomic Multiplatform for Alzheimer’s Disease Research (Raúl González-Domínguez, Álvaro González-Domínguez, Ana Sayago, Ángeles Fernández-Recamales)....Pages 125-137 Blood-Based Biomarker Screening with Agnostic Biological Definitions for an Accurate Diagnosis Within the Dimensional Spectrum of Neurodegenerative Diseases (Filippo Baldacci, Simone Lista, Sid E. O’Bryant, Roberto Ceravolo, Nicola Toschi, Harald Hampel et al.)....Pages 139-155 Front Matter ....Pages 157-157 Functional Magnetic Resonance Imaging in Alzheimer’ Disease Drug Development (Stefan Holiga, Ahmed Abdulkadir, Stefan Klöppel, Juergen Dukart)....Pages 159-163 Neuroimaging Methods for MRI Analysis in CSF Biomarkers Studies (Carles Falcon, Grégory Operto, José Luis Molinuevo, Juan Domingo Gispert)....Pages 165-184 Hybrid PET-MRI in Alzheimer’s Disease Research (Ismini C. Mainta, Maria I. Vargas, Sara Trombella, Giovanni B. Frisoni, Paul G. Unschuld, Valentina Garibotto)....Pages 185-200 Front Matter ....Pages 201-201 Amyloid PET Imaging: Standardization and Integration with Other Alzheimer’s Disease Biomarkers (Silvia Morbelli, Matteo Bauckneht)....Pages 203-212 The Use of 18F-FDG PET in the Diagnostic Workup of Alzheimer’s Dementia (Marion M. Ortner)....Pages 213-219 Quantification of Tau Load in Alzheimer’s Disease Clinical Trials Using Positron Emission Tomography (Tessa Timmers, Bart N. M. van Berckel, Adriaan A. Lammertsma, Rik Ossenkoppele)....Pages 221-229 Imaging Neuroinflammation: Quantification of Astrocytosis in a Multitracer PET Approach (Elena Rodriguez-Vieitez, Agneta Nordberg)....Pages 231-251 Front Matter ....Pages 253-253 Unbiased Lipidomics and Metabolomics of Human Brain Samples (Giuseppe Astarita, Matteo Stocchero, Giuseppe Paglia)....Pages 255-269 Neuropathological Assessment as an Endpoint in Clinical Trial Design (Steve Gentleman, Alan King Lun Liu)....Pages 271-279 Front Matter ....Pages 281-281 Analysis of Micro-RNA Expression by qPCR on a Microfluidics Platform for Alzheimer’s Disease Biomarker Discovery (Petros Takousis)....Pages 283-292 Telomere Length Shortening in Alzheimer’s Disease: Procedures for a Causal Investigation Using Single Nucleotide Polymorphisms in a Mendelian Randomization Study (Yiqiang Zhan, Sara Hägg)....Pages 293-306 Quantifying miRNA Deregulation in Alzheimer’s Disease (Ana L. Cardoso, Joana R. Guedes)....Pages 307-319 Front Matter ....Pages 321-321 Imaging of Microglial Activation in Alzheimer’s Disease by [11C]PBR28 PET (Cornelius K. Donat, Nazanin Mirzaei, Sac-Pharm Tang, Paul Edison, Magdalena Sastre)....Pages 323-339 In Vivo Two-Photon Calcium Imaging of Hippocampal Neurons in Alzheimer Mouse Models (Marc Aurel Busche)....Pages 341-351 Front Matter ....Pages 353-353 Cognitive Assessment in Alzheimer’s Disease Clinical Trials (Geraint Price)....Pages 355-362 Data Mining and Machine Learning Methods for Dementia Research (Rui Li)....Pages 363-370 Back Matter ....Pages 371-372